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Introduction and context {#s01}
========================

Although non-alcoholic fatty liver disease (NAFLD) was first described by Zelman \[[@bib-001]\] more than 65 years ago, only in 1980 did Ludwig and colleagues \[[@bib-002]\] define a new entity characterized by a type of fatty liver with inflammation, ballooned hepatocytes, and fibrosis, naming it 'non-alcoholic steatohepatitis' (NASH). NAFLD is now defined as fat accumulation in the liver exceeding 5-10% by weight in subjects without significant alcohol consumption (\<20 g/day, the equivalent of less than two or three glasses of wine per day) and without any other known causes of chronic liver disease. In clinical practice, the diagnosis of NAFLD is usually reached by ultrasonography that allows the detection of moderate to severe steatosis with a fair sensitivity and specificity, but only when fat on the liver biopsy exceeds 20-30%.

NAFLD and NASH are strictly correlated with the presence of insulin resistance (IR), which is often associated with central obesity, type 2 diabetes, and dyslipidemia, rendering liver steatosis the hepatic manifestation of metabolic syndrome (MS). The incidence of NAFLD/NASH is rapidly rising in adults and children due to the increased prevalence of obesity, type 2 diabetes, and metabolic diseases, and is now considered the most frequent cause of elevated liver enzymes \[[@bib-003],[@bib-004]\].

Population studies estimate that 20-25% of adults have NAFLD, and about 10% may progress to NASH, cirrhosis, and ultimately hepatocellular carcinoma over a period of 30-40 years \[[@bib-005]\]. In contrast, the overall survival due to increased risk for both cardiovascular and liver disease mortality is lower \[[@bib-006],[@bib-007]\]. Since hepatologists worldwide are facing an epidemiological explosion of this disease, several efforts are aimed at the early identification of subjects affected by NAFLD/NASH and at finding an effective treatment.

Recent advances {#s02}
===============

Progress in developing potential therapies for NAFLD/NASH has been made mainly by addressing the singular step involved in the pathogenesis of the diseases ([Figure 1](#fig-001){ref-type="fig"}). Agents reducing oxidative stress and/or apoptosis or showing cytoprotective properties have been evaluated with inconclusive results since the studies were conducted in small uncontrolled trials. At present, lifestyle interventions and behavior therapy, together with drugs used to treat the associated components of the MS (hypertension, diabetes, or dyslipidemia), represent the only therapeutic approach available to the clinician.

![Treatment targets according to the pathogenesis mechanisms of NAFLD and NASH](1757-5931-0001-0000000050-g001){#fig-001}

Lifestyle modifications {#s02_01}
-----------------------

Lifestyle modifications through a multidisciplinary approach, including dietary intervention, behavior therapy, and physical exercise, are the frontline therapy for this disease \[[@bib-008]\]. This is true not only in obese or overweight patients but also in normal-weight patients with cryptogenic NASH demonstrated by liver biopsy. Even though this approach could be ultimately cost-effective, it unfortunately is limited by the long-term compliance of the patients. Dietary intervention together with daily physical exercise is associated with a weight reduction and amelioration of IR and steatosis \[[@bib-009]-[@bib-012]\]. Both Suzuky and colleagues \[[@bib-012]\] in 2005 and more recently Harrison and Day \[[@bib-011]\] demonstrated that reducing weight by at least 5%, with subsequent weight control and regular exercise, improves or normalizes alanine aminotransferase (ALT) levels \[[@bib-012]\]; a reduction of body weight of more than 9% is associated with an improvement in hepatic histology \[[@bib-011],[@bib-013]\]. Modifications of diet to improve NAFLD or avoid the progression to NASH have been attempted recently in pilot studies and included both the reduction of saturated fatty acids and simple carbohydrate intake and the increase of polyunsaturated fatty acids and slowly adsorbed carbohydrates \[[@bib-014],[@bib-015]\]. Much-needed larger trials with appropriate histological follow-up are still lacking.

Pharmacotherapy {#s02_02}
---------------

### Oral hypoglycemic agents {#s02_02_01}

Insulin-sensitizing agents, namely metformin and the thiazolidinediones (TZDs) (also called glitazones), have been investigated in controlled trials. Many studies demonstrated an improvement of aminotransferase levels, IR, and histology after metformin treatment \[[@bib-016]\]. More recently, metformin has been found to modulate the expression of the pro-inflammatory tumor necrosis factor-alpha (TNF-α) cytokines \[[@bib-017]\] and to improve liver function and ecographic steatosis more than dietary modifications alone \[[@bib-018]\]. Also, TZDs (pioglitazone and rosiglitazone) are proving promising in the treatment of NASH, and various randomized long-term controlled studies in limited series have demonstrated a significant reduction in serum ALT and liver fat content associated with an improvement of IR and liver histology \[[@bib-019]\]. However, the main limitations of TZD therapy are the short duration of the beneficial effects after the drug is stopped and its contraindication in patients with heart disease \[[@bib-020]\]. Further larger studies are required.

### Weight-loss drugs {#s02_02_02}

Contradictory data have been published on the treatment of NASH with orlistat, a lipase inhibitor reducing fat absorption. In randomized placebo-controlled trials, orlistat led to an improvement in serum liver enzymes, ultrasound findings, and hepatic inflammation and fibrosis, but only in patients who maintained a significant weight reduction \[[@bib-021]\]. In another pilot study, which compared orlistat and sibutramine (an enhancer of satiety), it was demonstrated that treatment with both drugs led to liver enzyme improvement and liver fat reduction at ultrasound \[[@bib-022]\]. These data suggest a possible role of orlistat for NASH treatment in facilitating significant weight loss.

The endocannabinoid (EC) system, involved in the regulation of food intake and body weight, represents a novel target for medical therapy of NASH ([Figure 1](#fig-001){ref-type="fig"}). Rimonabant is a selective EC CB1 receptor antagonist decreasing hepatic lipogenesis and increasing satiety, adiponectin levels, and glucose uptake, thereby improving insulin levels and lipid profiles. In four large randomized placebo-controlled multicenter trials, rimonabant has been shown after 1 or 2 years of therapy to induce a greater significant average weight loss than placebo in obese patients, and more notably, a significant improvement in serum lipid profile, glycosylated hemoglobin, adiponectin, and C-reactive protein in patients with hyperlipidemia and diabetes. These impressive metabolic effects and preliminary animal studies, along with isolated case reports, suggested a direct effect of this medication on NASH and, in 2007, prompted two large multicenter trials. Unfortunately, both trials were interrupted by either American or European national medicine authorities (the US Food and Drug Administration and the European Medicine Agency, respectively) due to the development of significant psychiatric problems (severe depression and suicide) in some patients involved in the trial.

### Statins {#s02_02_03}

The role of statins in the treatment of NASH remains unclear. Recently, it was shown that patients treated with statins had a significant reduction in hepatic steatosis, liver enzymes, and TNF-α serum levels, and probably a low rate of fibrosis progression as well \[[@bib-023]\]. Although these early studies suggest that statins may be useful in hyperlipidemic NAFLD patients, controlled trials are necessary to validate these results.

### Anti-oxidants, cytoprotective agents, and other drugs {#s02_02_04}

Vitamin E, betaine, and ursodeoxycholic acid (UDCA) therapies have produced controversial results. Studies using vitamin E showed an improvement of liver function whereas others did not \[[@bib-024],[@bib-025]\]. Despite the preliminary results of some pilot studies demonstrating the protective role of UDCA in NAFLD, a large multicenter trial with a sufficiently large number of patients treated with UDCA or placebo for 2 years showed histological improvement in both the UDCA group and the placebo group \[[@bib-026]\]. It is possible that UDCA used in combination with other medications, as in the case of vitamin E, may improve liver function in NAFLD-affected patients \[[@bib-027]\].

Betaine, a metabolite that increases levels of S-adenosylmethionine, was used in a small uncontrolled study demonstrating an improvement in aminotransferase levels, steatosis, inflammation, and fibrosis after 1 year of treatment \[[@bib-028]\]. In two small studies, treatment with the angiotensin II blocker, losartan, also led to improvements in liver histology \[[@bib-029]\]. However, the very limited number of patients involved in these studies renders the results questionable.

### Bariatric surgery {#s02_02_05}

Bariatric surgery is suitable in severely obese patients, often affected by NAFLD, who failed to lose weight with nutritional counseling. Different surgical approaches are possible, and in general, liver histology improves significantly after bariatric surgery \[[@bib-030]\].

Implications for clinical practice {#s03}
==================================

The epidemiological explosion of obesity and diabetes in Western countries led to a parallel increase in the prevalence of NAFLD. Once the presence of fatty liver at ultrasound is recognized, it is important for the general practitioner and the hepatologist to consider NAFLD as a possible progressive liver disease, significantly associated with increased cardiovascular risks, which must be checked. Physicians have to exclude alcohol intake and to follow up NAFLD-affected patients to reduce the progression to NASH and other end-stage liver diseases. Despite its limitations, liver biopsy is still the gold standard for the diagnosis of NASH.

Once the diagnosis of NAFLD or NASH is reached, the main efforts must be focused on changing the lifestyle of the patient. Diet and physical exercise, which ideally should always be tailored to the individual, represent the only therapeutic approach available at present to treat NASH, by preventing cardiovascular risk and MS manifestations. This therapy needs a strong multidisciplinary counseling program to increase and maintain patient compliance. Enrolled patients should be referred to trained lifestyle therapists (dietitians, behavioral psychologists, physical activity supervisors, and case managers), and change in their social environment should be considered.

Other pharmacological or surgical treatments may be considered but only in patients with associated MS or severe obesity since no drugs or surgical procedures have been approved for the treatment of NAFLD or NASH. Larger multicenter clinical trials and validation studies are ongoing worldwide ([Table 1](#tbl-001){ref-type="table"}), and the ideal treatment for NASH will hopefully be found soon. Meanwhile, lifestyle interventions and behavior therapy must be introduced in clinical practice, possibly supported by public health programs, to change the environment of our 'fatty society'.

###### Promising agents and ongoing clinical trials \[[@bib-031]\] to treat NASH.
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                                                                                                                         Phase II study   Phase III study       
  --------------------------------- ------------------------------------------------------------------------------------ ---------------- ----------------- --- ---
  Diet Macronutrients               Omega-3 fatty acids                                                                  ×                                      
                                    Polyunsaturated fatty acids                                                          ×                                      
  Weight loss                       Orlistat                                                                                                                    ×
                                    Rimonabant                                                                                            ×                     
  Antioxidants                      Silymarin                                                                                             ×                     
                                    Pentoxifilline                                                                       ×                                      
                                    Pentoxifilline versus pioglitazone                                                   ×                                      
                                    SAMe                                                                                 ×                                      
                                    Iron depletion                                                                       ×                                      
                                    Mitochondrial protection (TRO19662)                                                  ×                                      
  Inflammation and fibrosis         PDE4 inhibitor                                                                       ×                                      
  Reduction of insulin resistance   Metformin versus vitamin E versus placebo (TONIC)                                                                           ×
                                    Pioglitazone versus metformin versus placebo (PIVENS)                                                                       ×
                                    Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan                                      ×   

NASH, non-alcoholic steatohepatitis; PDE4, phosphodiesterase-4; PIVENS, Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients with Non-alcoholic Steatohepatitis; SAMe, S-adenosylmethionine; TONIC, Treatment of Non-alcoholic Fatty Liver Disease in Children.
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